Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells.

Braciak TA, Roskopf CC, Wildenhain S, Fenn NC, Schiller CB, Schubert IA, Jacob U, Honegger A, Krupka C, Subklewe M, Spiekermann K, Hopfner KP, Fey GH, Aigner M, Krause S, Mackensen A, Oduncu FS.

Oncoimmunology. 2018 Jul 30;7(9):e1472195. doi: 10.1080/2162402X.2018.1472195. eCollection 2018.

2.

CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells.

Schiller CB, Braciak TA, Fenn NC, Seidel UJ, Roskopf CC, Wildenhain S, Honegger A, Schubert IA, Schele A, Lämmermann K, Fey GH, Jacob U, Lang P, Hopfner KP, Oduncu FS.

Oncotarget. 2016 Dec 13;7(50):83392-83408. doi: 10.18632/oncotarget.13110.

3.

A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.

Amoury M, Mladenov R, Nachreiner T, Pham AT, Hristodorov D, Di Fiore S, Helfrich W, Pardo A, Fey G, Schwenkert M, Thepen T, Kiessling F, Hussain AF, Fischer R, Kolberg K, Barth S.

Int J Cancer. 2016 Aug 15;139(4):916-27. doi: 10.1002/ijc.30119. Epub 2016 Apr 15.

4.

Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells.

Roskopf CC, Braciak TA, Fenn NC, Kobold S, Fey GH, Hopfner KP, Oduncu FS.

Oncotarget. 2016 Apr 19;7(16):22579-89. doi: 10.18632/oncotarget.8022.

5.

Chip-based platform for dynamic analysis of NK cell cytolysis mediated by a triplebody.

Chatzopoulou EI, Roskopf CC, Sekhavati F, Braciak TA, Fenn NC, Hopfner KP, Oduncu FS, Fey GH, Rädler JO.

Analyst. 2016 Apr 7;141(7):2284-95. doi: 10.1039/c5an02585k.

PMID:
26958659
6.

Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone.

Krug C, Birkholz K, Paulus A, Schwenkert M, Schmidt P, Hoffmann N, Hombach A, Fey G, Abken H, Schuler G, Schuler-Thurner B, Dörrie J, Schaft N.

Cancer Immunol Immunother. 2015 Dec;64(12):1623-35. doi: 10.1007/s00262-015-1767-4. Epub 2015 Oct 29.

PMID:
26515978
7.

Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.

O'Hear C, Heiber JF, Schubert I, Fey G, Geiger TL.

Haematologica. 2015 Mar;100(3):336-44. doi: 10.3324/haematol.2014.112748. Epub 2014 Dec 5.

8.

T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cell.

Roskopf CC, Schiller CB, Braciak TA, Kobold S, Schubert IA, Fey GH, Hopfner KP, Oduncu FS.

Oncotarget. 2014 Aug 15;5(15):6466-83.

9.

A CSPG4-specific immunotoxin kills rhabdomyosarcoma cells and binds to primary tumor tissues.

Brehm H, Niesen J, Mladenov R, Stein C, Pardo A, Fey G, Helfrich W, Fischer R, Gattenlöhner S, Barth S.

Cancer Lett. 2014 Oct 1;352(2):228-35. doi: 10.1016/j.canlet.2014.07.006. Epub 2014 Jul 10.

PMID:
25016058
10.

NK cells from an AML patient have recovered in remission and reached comparable cytolytic activity to that of a healthy monozygotic twin mediated by the single-chain triplebody SPM-2.

Braciak TA, Wildenhain S, Roskopf CC, Schubert IA, Fey GH, Jacob U, Hopfner KP, Oduncu FS.

J Transl Med. 2013 Nov 16;11:289. doi: 10.1186/1479-5876-11-289.

11.

A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells.

Schubert I, Saul D, Nowecki S, Mackensen A, Fey GH, Oduncu FS.

MAbs. 2014 Jan-Feb;6(1):286-96.

12.

A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting.

Schubert I, Kellner C, Stein C, Kügler M, Schwenkert M, Saul D, Stockmeyer B, Berens C, Oduncu FS, Mackensen A, Fey GH.

MAbs. 2012 Jan-Feb;4(1):45-56. doi: 10.4161/mabs.4.1.18498.

13.

Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.

Repp R, Kellner C, Muskulus A, Staudinger M, Nodehi SM, Glorius P, Akramiene D, Dechant M, Fey GH, van Berkel PH, van de Winkel JG, Parren PW, Valerius T, Gramatzki M, Peipp M.

J Immunol Methods. 2011 Oct 28;373(1-2):67-78. doi: 10.1016/j.jim.2011.08.003. Epub 2011 Aug 9.

PMID:
21855548
14.

Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells.

Kellner C, Bruenke J, Horner H, Schubert J, Schwenkert M, Mentz K, Barbin K, Stein C, Peipp M, Stockmeyer B, Fey GH.

Cancer Lett. 2011 Apr 28;303(2):128-39. doi: 10.1016/j.canlet.2011.01.020. Epub 2011 Feb 19.

PMID:
21339041
15.

Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo.

de Bruyn M, Rybczynska AA, Wei Y, Schwenkert M, Fey GH, Dierckx RA, van Waarde A, Helfrich W, Bremer E.

Mol Cancer. 2010 Nov 23;9:301. doi: 10.1186/1476-4598-9-301.

16.

A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting.

Schubert I, Kellner C, Stein C, Kügler M, Schwenkert M, Saul D, Mentz K, Singer H, Stockmeyer B, Hillen W, Mackensen A, Fey GH.

MAbs. 2011 Jan-Feb;3(1):21-30. Epub 2011 Jan 1.

17.

A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting.

Kügler M, Stein C, Kellner C, Mentz K, Saul D, Schwenkert M, Schubert I, Singer H, Oduncu F, Stockmeyer B, Mackensen A, Fey GH.

Br J Haematol. 2010 Sep;150(5):574-86. doi: 10.1111/j.1365-2141.2010.08300.x. Epub 2010 Jul 16.

PMID:
20636437
18.

Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation.

Birkholz K, Schwenkert M, Kellner C, Gross S, Fey G, Schuler-Thurner B, Schuler G, Schaft N, Dörrie J.

Blood. 2010 Sep 30;116(13):2277-85. doi: 10.1182/blood-2010-02-268425. Epub 2010 Jun 21.

19.

Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16.

Singer H, Kellner C, Lanig H, Aigner M, Stockmeyer B, Oduncu F, Schwemmlein M, Stein C, Mentz K, Mackensen A, Fey GH.

J Immunother. 2010 Jul-Aug;33(6):599-608. doi: 10.1097/CJI.0b013e3181dda225.

PMID:
20551837
20.

Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems.

Rothdiener M, Müller D, Castro PG, Scholz A, Schwemmlein M, Fey G, Heidenreich O, Kontermann RE.

J Control Release. 2010 Jun 1;144(2):251-8. doi: 10.1016/j.jconrel.2010.02.020. Epub 2010 Feb 22.

PMID:
20184933
21.

Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells.

Stein C, Kellner C, Kügler M, Reiff N, Mentz K, Schwenkert M, Stockmeyer B, Mackensen A, Fey GH.

Br J Haematol. 2010 Mar;148(6):879-89. doi: 10.1111/j.1365-2141.2009.08033.x. Epub 2010 Jan 8.

PMID:
20064159
22.

A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.

Guettinger Y, Barbin K, Peipp M, Bruenke J, Dechant M, Horner H, Thierschmidt D, Valerius T, Repp R, Fey GH, Stockmeyer B.

J Immunol. 2010 Feb 1;184(3):1210-7. doi: 10.4049/jimmunol.0902033. Epub 2009 Dec 30.

23.

A simple one-pot route to mesoporous silicas SBA-15 functionalized with exceptionally high loadings of pendant carboxylic acid groups.

Tsai CT, Pan YC, Ting CC, Vetrivel S, Chiang AS, Fey GT, Kao HM.

Chem Commun (Camb). 2009 Sep 7;(33):5018-20. doi: 10.1039/b909680a. Epub 2009 Jul 14.

PMID:
19668835
24.

A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability.

ten Cate B, Bremer E, de Bruyn M, Bijma T, Samplonius D, Schwemmlein M, Huls G, Fey G, Helfrich W.

Leukemia. 2009 Aug;23(8):1389-97. doi: 10.1038/leu.2009.34. Epub 2009 Mar 5.

PMID:
19262596
25.

Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework.

Kügler M, Stein C, Schwenkert M, Saul D, Vockentanz L, Huber T, Wetzel SK, Scholz O, Plückthun A, Honegger A, Fey GH.

Protein Eng Des Sel. 2009 Mar;22(3):135-47. doi: 10.1093/protein/gzn079. Epub 2009 Feb 1.

26.

A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.

Kellner C, Bruenke J, Stieglmaier J, Schwemmlein M, Schwenkert M, Singer H, Mentz K, Peipp M, Lang P, Oduncu F, Stockmeyer B, Fey GH.

J Immunother. 2008 Nov-Dec;31(9):871-84. doi: 10.1097/CJI.0b013e318186c8b4.

PMID:
18833000
27.

T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice.

Kumar P, Ban HS, Kim SS, Wu H, Pearson T, Greiner DL, Laouar A, Yao J, Haridas V, Habiro K, Yang YG, Jeong JH, Lee KY, Kim YH, Kim SW, Peipp M, Fey GH, Manjunath N, Shultz LD, Lee SK, Shankar P.

Cell. 2008 Aug 22;134(4):577-86. doi: 10.1016/j.cell.2008.06.034. Epub 2008 Aug 7.

28.

A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells.

Schwenkert M, Birkholz K, Schwemmlein M, Kellner C, Kügler M, Peipp M, Nettelbeck DM, Schuler-Thurner B, Schaft N, Dörrie J, Ferrone S, Kämpgen E, Fey GH.

Melanoma Res. 2008 Apr;18(2):73-84. doi: 10.1097/CMR.0b013e3282f7c8f9.

29.

Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists.

Bremer E, ten Cate B, Samplonius DF, Mueller N, Wajant H, Stel AJ, Chamuleau M, van de Loosdrecht AA, Stieglmaier J, Fey GH, Helfrich W.

Cancer Res. 2008 Jan 15;68(2):597-604. doi: 10.1158/0008-5472.CAN-07-5171.

30.

Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein.

Stieglmaier J, Bremer E, Kellner C, Liebig TM, ten Cate B, Peipp M, Schulze-Koops H, Pfeiffer M, Bühring HJ, Greil J, Oduncu F, Emmerich B, Fey GH, Helfrich W.

Cancer Immunol Immunother. 2008 Feb;57(2):233-46. Epub 2007 Jul 31.

PMID:
17665197
31.

A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells.

Schwemmlein M, Stieglmaier J, Kellner C, Peipp M, Saul D, Oduncu F, Emmerich B, Stockmeyer B, Lang P, Beck JD, Fey GH.

Leukemia. 2007 Jul;21(7):1405-12. Epub 2007 May 10.

PMID:
17495978
32.

A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells.

Schwemmlein M, Peipp M, Barbin K, Saul D, Stockmeyer B, Repp R, Birkmann J, Oduncu F, Emmerich B, Fey GH.

Br J Haematol. 2006 Apr;133(2):141-51.

PMID:
16611304
33.

Influence of variable N-glycosylation on the cytolytic potential of chimeric CD19 antibodies.

Barbin K, Stieglmaier J, Saul D, Stieglmaier K, Stockmeyer B, Pfeiffer M, Lang P, Fey GH.

J Immunother. 2006 Mar-Apr;29(2):122-33.

PMID:
16531813
34.

Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).

Bruenke J, Barbin K, Kunert S, Lang P, Pfeiffer M, Stieglmaier K, Niethammer D, Stockmeyer B, Peipp M, Repp R, Valerius T, Fey GH.

Br J Haematol. 2005 Jul;130(2):218-28.

PMID:
16029450
35.

Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.

Bremer E, Samplonius DF, Peipp M, van Genne L, Kroesen BJ, Fey GH, Gramatzki M, de Leij LF, Helfrich W.

Cancer Res. 2005 Apr 15;65(8):3380-8.

36.

Peritoneal carcinomatosis from cervical cancer detected by F-18 FDG positron emission tomography.

Spottswood SE, Lopatina OA, Fey GL, Boardman CH.

Clin Nucl Med. 2005 Jan;30(1):56-9. No abstract available.

PMID:
15604978
37.

Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor.

Hofmann H, Geier M, Marzi A, Krumbiegel M, Peipp M, Fey GH, Gramberg T, Pöhlmann S.

Biochem Biophys Res Commun. 2004 Jul 9;319(4):1216-21.

PMID:
15194496
38.

A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells.

Bruenke J, Fischer B, Barbin K, Schreiter K, Wachter Y, Mahr K, Titgemeyer F, Niederweis M, Peipp M, Zunino SJ, Repp R, Valerius T, Fey GH.

Br J Haematol. 2004 Apr;125(2):167-79.

PMID:
15059139
39.

2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography uptake in systemic lupus erythematosus-associated adenopathy.

Fey GL, Jolles PR, Buckley LM, Massey GV.

Mol Imaging Biol. 2004 Jan-Feb;6(1):7-11.

PMID:
15018823
40.

Efficient eukaryotic expression of fluorescent scFv fusion proteins directed against CD antigens for FACS applications.

Peipp M, Saul D, Barbin K, Bruenke J, Zunino SJ, Niederweis M, Fey GH.

J Immunol Methods. 2004 Feb 15;285(2):265-80.

PMID:
14980440
41.

Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts.

Lang P, Barbin K, Feuchtinger T, Greil J, Peipp M, Zunino SJ, Pfeiffer M, Handgretinger R, Niethammer D, Fey GH.

Blood. 2004 May 15;103(10):3982-5. Epub 2004 Feb 5.

42.

A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells.

Peipp M, Küpers H, Saul D, Schlierf B, Greil J, Zunino SJ, Gramatzki M, Fey GH.

Cancer Res. 2002 May 15;62(10):2848-55.

44.

Biased distribution of chromosomal breakpoints involving the MLL gene in infants versus children and adults with t(4;11) ALL.

Reichel M, Gillert E, Angermüller S, Hensel JP, Heidel F, Lode M, Leis T, Biondi A, Haas OA, Strehl S, Panzer-Grümayer ER, Griesinger F, Beck JD, Greil J, Fey GH, Uckun FM, Marschalek R.

Oncogene. 2001 May 24;20(23):2900-7.

45.

An improved procedure for the generation of recombinant single-chain Fv antibody fragments reacting with human CD13 on intact cells.

Peipp M, Simon N, Loichinger A, Baum W, Mahr K, Zunino SJ, Fey GH.

J Immunol Methods. 2001 May 1;251(1-2):161-76.

PMID:
11292491
46.

Rapid isolation of chromosomal breakpoints from patients with t(4;11) acute lymphoblastic leukemia: implications for basic and clinical research.

Reichel M, Gillert E, Breitenlohner I, Angermüller S, Fey GH, Marschalek R, Repp R, Greil J, Beck JD.

Leukemia. 2001 Feb;15(2):286-8. No abstract available.

PMID:
11236948
47.

Detection of antigen-specific human serum proteins related to the T-cell receptor in infectious disease and in an immune response to milk proteins or chemicals.

Little CH, Georgiou GM, Fey G, Ravindran B, Levine J, Ogedegbe H, Yamase H, Cone RE.

Proc Soc Exp Biol Med. 2000 Sep;224(4):264-72.

PMID:
10964261
48.

Rab11b is essential for recycling of transferrin to the plasma membrane.

Schlierf B, Fey GH, Hauber J, Hocke GM, Rosorius O.

Exp Cell Res. 2000 Aug 25;259(1):257-65.

PMID:
10942597
49.

ENL, the MLL fusion partner in t(11;19), binds to the c-Abl interactor protein 1 (ABI1) that is fused to MLL in t(10;11)+.

García-Cuéllar MP, Schreiner SA, Birke M, Hamacher M, Fey GH, Slany RK.

Oncogene. 2000 Mar 30;19(14):1744-51.

50.

Regulation of CD95 expression and CD95-mediated cell death by interferon-gamma in acute lymphoblastic leukemia with chromosomal translocation t(4;11).

Dörrie J, Schuh W, Keil A, Bongards E, Greil J, Fey GH, Zunino SJ.

Leukemia. 1999 Oct;13(10):1539-47.

PMID:
10516755

Supplemental Content

Support Center